Renaissance Technologies (RenTech)'s ENTA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 557,600 shares of Enanta Pharmaceuticals, Inc. (ENTA) worth $8.13 M, representing 0.01% of the portfolio. First purchased in 2013-Q4, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in ENTA, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2016, adding 549,200 shares. Largest reduction occurred in Q1 2019, reducing 151,695 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Enanta Pharmaceuticals (ENTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Enanta Pharmaceuticals (ENTA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -107,658 | Reduce 16.18% | 557,600 | $14.58 |
| Q1 2026 | +23,058 | Add 3.59% | 665,258 | $12.63 |
| Q4 2025 | +162,600 | Add 33.90% | 642,200 | $15.77 |
| Q3 2025 | +10,100 | Add 2.15% | 479,600 | $11.97 |
| Q2 2025 | +5,900 | Add 1.27% | 469,500 | $7.56 |
| Q1 2025 | -34,400 | Reduce 6.91% | 463,600 | $5.52 |
| Q4 2024 | -26,900 | Reduce 5.12% | 498,000 | $5.75 |
| Q3 2024 | +14,000 | Add 2.74% | 524,900 | $10.36 |
| Q2 2024 | -15,200 | Reduce 2.89% | 510,900 | $12.97 |
| Q1 2024 | -32,400 | Reduce 5.80% | 526,100 | $17.46 |
| Q4 2023 | +100,400 | Add 21.92% | 558,500 | $9.41 |
| Q3 2023 | -18,200 | Reduce 3.82% | 458,100 | $11.17 |
| Q2 2023 | +48,836 | Add 11.42% | 476,300 | $0.02 |
| Q1 2023 | -45,736 | Reduce 9.67% | 427,464 | $0.04 |
| Q4 2022 | +5,200 | Add 1.11% | 473,200 | $0.05 |
| Q3 2022 | -74,800 | Reduce 13.78% | 468,000 | $51.87 |
| Q2 2022 | -64,300 | Reduce 10.59% | 542,800 | $47.27 |
| Q1 2022 | -107,300 | Reduce 15.02% | 607,100 | $71.18 |
| Q4 2021 | -42,185 | Reduce 5.58% | 714,400 | $74.78 |
| Q3 2021 | -41,143 | Reduce 5.16% | 756,585 | $56.81 |
| Q2 2021 | -102,472 | Reduce 11.38% | 797,728 | $44.01 |
| Q1 2021 | -133,700 | Reduce 12.93% | 900,200 | $49.32 |
| Q4 2020 | +4,900 | Add 0.48% | 1.03 M | $42.10 |
| Q3 2020 | +86,100 | Add 9.13% | 1.03 M | $45.78 |
| Q2 2020 | +62,300 | Add 7.07% | 942,900 | $50.21 |
| Q1 2020 | +149,000 | Add 20.37% | 880,600 | $51.43 |
| Q4 2019 | +68,700 | Add 10.36% | 731,600 | $61.78 |
| Q3 2019 | +112,600 | Add 20.46% | 662,900 | $60.08 |
| Q2 2019 | -95,205 | Reduce 14.75% | 550,300 | $84.38 |
| Q1 2019 | -151,695 | Reduce 19.03% | 645,505 | $95.52 |
| Q4 2018 | -51,200 | Reduce 6.03% | 797,200 | $70.83 |
| Q3 2018 | -30,100 | Reduce 3.43% | 848,400 | $85.46 |
| Q2 2018 | +33,600 | Add 3.98% | 878,500 | $115.90 |
| Q1 2018 | +73,300 | Add 9.50% | 844,900 | $80.91 |
| Q4 2017 | +90,500 | Add 13.29% | 771,600 | $58.68 |
| Q3 2017 | +60,600 | Add 9.77% | 681,100 | $46.80 |
| Q2 2017 | +52,807 | Add 9.30% | 620,500 | $35.98 |
| Q1 2017 | -7,078 | Reduce 1.23% | 567,693 | $30.80 |
| Q4 2016 | -126,629 | Reduce 18.05% | 574,771 | $33.50 |
| Q3 2016 | +549,200 | Add 360.84% | 701,400 | $26.61 |
| Q2 2016 | +96,600 | Add 173.74% | 152,200 | $22.05 |
| Q1 2016 | +55,600 | New Buy | 55,600 | $29.37 |
| Q4 2014 | -83,277 | Sold Out | 0 | $0.00 |
| Q3 2014 | +28,677 | Add 52.52% | 83,277 | $39.57 |
| Q2 2014 | +54,600 | New Buy | 54,600 | $43.08 |
| Q1 2014 | -64,300 | Sold Out | 0 | $0.00 |
| Q4 2013 | +64,300 | New Buy | 64,300 | $27.28 |
Renaissance Technologies (RenTech)'s Enanta Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Enanta Pharmaceuticals, Inc. (ENTA) in Q4 2013, acquiring 64,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Enanta Pharmaceuticals, Inc. (ENTA) for 47 quarters since Q4 2013.
Renaissance Technologies (RenTech)'s largest addition to Enanta Pharmaceuticals, Inc. (ENTA) was in Q3 2016, adding 701,400 shares worth $18.66 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 557,600 shares of Enanta Pharmaceuticals, Inc. (ENTA), valued at approximately $8.13 M.
As of the Q2 2026 filing, Enanta Pharmaceuticals, Inc. (ENTA) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Enanta Pharmaceuticals, Inc. (ENTA) was 1,033,900 shares, as reported at the end of Q4 2020.